GLP-1 · Cost
How Much Does Tirzepatide Cost? Zepbound, Mounjaro, and Every Way to Pay
Educational guide · By ClearHormones Editorial Team · Updated July 2026
Tirzepatide has no single price. What you pay depends on which brand you are prescribed (Zepbound for weight or Mounjaro for type 2 diabetes), whether you have insurance that covers it, whether you qualify for the manufacturer's savings card, and whether you buy the FDA-approved pen or vial versus a compounded copy. The same molecule can cost dramatically different amounts on the same day for two different people, so the honest answer is a range of cost paths rather than one number.
The short answer
Tirzepatide is the active ingredient in two FDA-approved Eli Lilly injectables: Zepbound, approved for chronic weight management, and Mounjaro, approved for type 2 diabetes. Because they share a molecule but not an indication, insurers treat them very differently, and the cheapest legitimate path for one person may be closed to another. The five paths that actually determine your out-of-pocket cost are: the manufacturer list price, an insured copay, the Lilly commercial savings card, self-pay vials, and compounded tirzepatide (which is not an FDA-approved product).
Because published prices change and vary by pharmacy and plan, this page maps the cost structure and points you to Lilly's own coverage and savings pages for the live figure, rather than quoting a number that could be stale or wrong by the time you read it. Chase the structure first; the structure tells you which door to knock on.
Why there is no single tirzepatide price
Tirzepatide reaches patients under two brand names, and the brand you are prescribed changes almost everything about what you pay. Zepbound is FDA-approved for chronic weight management. Mounjaro is FDA-approved for type 2 diabetes. Both are made by Eli Lilly and both are tirzepatide, but they are priced, packaged, and covered as separate products.
On top of the brand split, four other variables move the number: whether your insurance lists the drug on its formulary, whether your plan applies a copay or coinsurance, whether you qualify for the manufacturer's savings card, and whether you buy the FDA-approved pen, a self-pay vial, or a compounded version. Stack those variables and you get a wide spread of real-world costs for one molecule.
This is why a friend's price tells you almost nothing about yours. Two people prescribed the same tirzepatide dose on the same day can pay very different amounts because they entered through different doors: one through commercial insurance plus a savings card, the other through cash self-pay. The useful question is not what does tirzepatide cost but which cost path am I eligible for.
The five cost paths, compared
Every legitimate way to pay for tirzepatide falls into one of five structures. The table below lays out what each path is, who it typically fits, and where the actual dollar figure comes from. Notice that only the manufacturer's own pages can supply a specific list or savings price, which is why the live number lives there and not here.
The most common mistake is assuming the list price is what you will pay. For most insured patients it is not; for cash patients, the self-pay vial route usually beats paying full list price at the pharmacy counter. Read the paths as doors, and start with the one your coverage situation opens.
| Cost path | What it is | Who it typically fits | Where the real number comes from |
|---|---|---|---|
| Manufacturer list price | The published price before any insurance or discount | Almost no one pays this in full; it is the sticker, not the checkout | Lilly's Zepbound or Mounjaro savings pages |
| Insured copay / coinsurance | Your share after a plan that covers the drug pays its part | People whose commercial or government plan lists tirzepatide on formulary | Your plan's formulary and pharmacy benefit |
| Lilly commercial savings card | A manufacturer copay card that lowers cost for eligible commercially insured patients | People with commercial insurance (typically excludes Medicare/Medicaid) | Lilly's Zepbound or Mounjaro savings pages |
| Self-pay vials | Lower-cost cash single-dose vials sold directly | Cash payers without weight-loss coverage | Lilly's Zepbound coverage & savings page |
| Compounded tirzepatide | A non-FDA-approved copy made by a compounding pharmacy | Often the cheapest, but not an FDA-approved product | The compounder; no manufacturer or FDA price exists |
List price versus what you actually pay
The list price is the manufacturer's published sticker before insurance, rebates, or savings programs. It is real, but it is almost never the amount a patient hands over at the pharmacy. Insurers negotiate off it, savings cards discount from it, and cash programs route around it entirely.
Treating the list price as your cost leads people to two errors: giving up because the sticker looks impossible, or overpaying because they never asked about the cheaper doors. The list price matters mainly as a ceiling and as the baseline that copay cards discount from. Lilly publishes the current list figures on its Zepbound and Mounjaro savings pages; check there rather than trusting a number quoted secondhand, because these figures change.
If you have no coverage for the drug and no savings-card eligibility, the relevant comparison is not list price versus zero. It is list-price pens versus self-pay vials versus a compounded copy, each with different tradeoffs in price, convenience, and safety.
What insurance coverage actually looks like
Commercial insurance is where tirzepatide coverage is most winnable, but it is far from automatic. Many employer plans cover Mounjaro for type 2 diabetes while excluding or restricting weight-management drugs like Zepbound, because obesity coverage is a separate benefit decision the plan sponsor makes. Two people at different companies with identical BMIs can have opposite coverage outcomes.
Medicare has historically not covered medications prescribed solely for weight loss, which affects Zepbound access for many older adults, while diabetes-indicated use of Mounjaro follows different rules. Medicaid coverage of weight-management drugs varies state by state. Because these rules shift, verify your specific plan's formulary rather than assuming, and ask directly whether prior authorization or step therapy applies.
Prior authorization is the most common gate. Plans that do cover tirzepatide often require documentation that you meet the FDA label criteria, and for weight management that means the label's BMI thresholds: a BMI of 30 or higher, or a BMI of 27 or higher together with at least one weight-related condition such as hypertension, type 2 diabetes, or dyslipidemia. Having that documentation ready speeds approval and lowers cost.
The Lilly savings card, and who it excludes
For people with commercial insurance, the manufacturer savings card is often the single biggest lever on out-of-pocket cost. Lilly offers copay-card programs for both Zepbound and Mounjaro that reduce the amount eligible patients pay, with terms that differ depending on whether your commercial plan covers the drug or not.
The crucial eligibility line is government insurance. Manufacturer copay cards generally exclude patients enrolled in Medicare, Medicaid, or other federal or state healthcare programs. If that is your coverage, the savings card is usually not an option, and the self-pay route becomes more relevant. The exact eligibility rules, dollar caps, and enrollment steps are published on Lilly's Zepbound and Mounjaro savings pages, and they change, so confirm the current terms before you count on a figure.
Savings cards also carry maximum-benefit and expiration limits, so the discount you see in month one may not hold indefinitely. Read the fine print for the annual cap and re-enrollment requirements so a price you budgeted around does not quietly reset.
Self-pay vials: the cash route for people without weight-loss coverage
Lilly sells single-dose tirzepatide vials as a lower-cost, cash-pay option aimed at people whose insurance does not cover weight management. Vials are filled and self-administered differently from the autoinjector pens, and the tradeoff is a lower price in exchange for a slightly more hands-on process. For a cash payer, this route typically undercuts paying full list price for pens at a retail pharmacy.
The current self-pay vial pricing, the doses offered, and the ordering steps are published on Lilly's Zepbound coverage and savings page. Because the manufacturer adjusts these programs over time, treat that page as the source of truth for the live number rather than any figure quoted elsewhere.
Self-pay vials are an FDA-approved product from the manufacturer, which distinguishes them cleanly from compounded copies. If cost is your barrier and you want to stay inside the FDA-approved supply, this is the route to price out first before considering compounding.
Compounded tirzepatide: cheaper, but not FDA-approved
Compounded tirzepatide is often marketed at a lower monthly price than the branded pens or vials, which is why it spread quickly through telehealth and med-spa channels. The price advantage is real, but so is the tradeoff: compounded tirzepatide is not an FDA-approved product. The FDA does not review compounded versions for safety, effectiveness, or manufacturing quality the way it does the branded drug.
The FDA has warned about unapproved and compounded GLP-1 products, including concerns about dosing errors and product quality. Legal availability of compounded tirzepatide also shifted with the drug's shortage status, because large-scale compounding of a drug is tied to whether the FDA lists it as in shortage. That means the compounded market is a moving legal target, not a stable long-term supply.
The honest framing is that compounded tirzepatide trades a lower price for lost FDA oversight. That may be an acceptable tradeoff to some patients and an unacceptable one to others, but it should be a deliberate choice, not a default made because a website quoted a low number. Discuss it with a licensed prescriber rather than a marketing page.
Zepbound versus Mounjaro: why the indication changes your cost
Because Zepbound and Mounjaro are the same molecule, patients sometimes ask whether they can just get the cheaper or more-covered one. The answer is bounded by what each is approved for. Zepbound is approved for weight management; Mounjaro is approved for type 2 diabetes. Prescribing Mounjaro for weight loss alone is off-label, and off-label use for weight is rarely covered by insurers, which undercuts the supposed savings.
For someone with type 2 diabetes, Mounjaro coverage is often the more established path, because diabetes drugs are more consistently on formularies than weight-management drugs. For someone whose goal is weight management without diabetes, Zepbound is the on-label choice, and the cost conversation runs through weight-management coverage, the savings card, or self-pay vials.
The takeaway: the cheaper brand on paper is not automatically cheaper for you, because coverage follows the approved indication. Match the brand to your actual diagnosis and let that determine which cost paths are genuinely open.
A note for women: the birth-control interaction is a hidden cost
Cost is not only measured in dollars. For women using oral contraceptives, tirzepatide carries a specific clinical consideration that semaglutide does not: tirzepatide can reduce the effectiveness of oral birth control. The FDA labeling for tirzepatide advises appropriate precautions around this interaction.
The practical implication is that starting tirzepatide may mean adjusting contraception, for example adding a barrier method or switching to a non-oral method for a period after starting or changing dose. That is a real part of the decision, and ignoring it to chase the lowest sticker price is a false economy.
This is the kind of tradeoff worth raising directly with a prescriber before you commit to a cost path. The cheapest supply is not a bargain if it comes without a clinician who flags interactions that matter for your body and your plans.
How to get tirzepatide legally and safely
Tirzepatide is a prescription medication. There is no legitimate path to buy it without a prescription, and any seller offering to skip that step is a red flag, not a discount. The legal route runs through a licensed prescriber who confirms you meet the eligibility criteria, a genuine medical evaluation, and a licensed pharmacy that dispenses the FDA-approved product.
For weight management, eligibility follows the FDA label: a BMI of 30 or higher, or 27 or higher with at least one weight-related condition. A legitimate telehealth service will assess this, review your history and medications, and prescribe only if appropriate, rather than approving everyone who fills out a form. If a provider prescribes without any of that, treat it as a warning sign.
This site does not sell or prescribe tirzepatide. If you want to explore access, the safe move is to compare providers licensed in your state and confirm they dispense FDA-approved medication through a licensed pharmacy, then let a real clinical evaluation determine both the prescription and the cost path that fits your coverage.
How to lower your tirzepatide cost, step by step
Start by identifying your coverage type, because it decides which doors are open. If you have commercial insurance, check your formulary for tirzepatide and, in parallel, look at the Lilly savings card terms for your brand. If your plan covers the drug, the savings card on top of a covered copay is usually the lowest legitimate cost.
If you have commercial insurance but no weight-management coverage, price the self-pay vials against the savings card's cash terms, since Lilly's savings programs sometimes extend to patients whose plans do not cover the drug. If you have Medicare, Medicaid, or other government insurance, assume the manufacturer savings card is off the table and compare your covered options against self-pay vials directly.
Before defaulting to a compounded copy for price alone, price out the FDA-approved self-pay vial first, get any required prior-authorization documentation together to unlock coverage, and confirm the live figures on Lilly's savings pages rather than trusting a quoted number. The lowest sustainable cost is usually the FDA-approved path that your specific coverage makes cheapest, not the lowest sticker on a marketing page.
Frequently asked questions
- What is the cheapest way to get tirzepatide?
- It depends on your coverage. For commercially insured patients whose plan covers the drug, a covered copay plus the Lilly savings card is usually cheapest. For cash payers without weight-loss coverage, Lilly's self-pay vials are typically the lowest-cost FDA-approved route. Compounded tirzepatide is often cheaper still but is not FDA-approved. Check Lilly's savings pages for live figures.
- Is Zepbound or Mounjaro cheaper?
- They are the same molecule, but cost follows the approved use. Mounjaro is approved for type 2 diabetes and is more consistently covered by insurers; Zepbound is approved for weight management, where coverage varies. Using Mounjaro for weight alone is off-label and rarely covered, so the brand that is cheaper for you depends on your diagnosis and plan, not the sticker price.
- Does insurance cover tirzepatide?
- Sometimes. Commercial plans often cover Mounjaro for type 2 diabetes, while weight-management coverage for Zepbound varies by employer plan. Medicare has historically not covered drugs prescribed solely for weight loss, and Medicaid coverage varies by state. Many plans require prior authorization confirming you meet the FDA label criteria. Verify your specific formulary rather than assuming.
- Why is compounded tirzepatide so much cheaper?
- Compounded tirzepatide is made by compounding pharmacies and is not an FDA-approved product, so it is not reviewed for safety, effectiveness, or manufacturing quality the way the branded drug is. The FDA has warned about unapproved GLP-1 products, and legal availability shifted with the drug's shortage status. The lower price comes at the cost of FDA oversight.
- Can I get tirzepatide without insurance?
- Yes, through cash self-pay. Lilly sells single-dose tirzepatide vials as a lower-cost option for people without weight-loss coverage, and the current price and ordering steps are on Lilly's Zepbound coverage and savings page. You still need a valid prescription from a licensed prescriber; there is no legal way to buy tirzepatide without one.
- Who qualifies for the Lilly savings card?
- The savings card is generally for patients with commercial insurance. It typically excludes people enrolled in Medicare, Medicaid, or other government healthcare programs. Terms, dollar caps, and eligibility differ by brand and change over time, so confirm the current rules on Lilly's Zepbound or Mounjaro savings pages before relying on a figure.
- Is tirzepatide safe to use with birth control pills?
- Tirzepatide can reduce the effectiveness of oral contraceptives, according to its FDA labeling, and semaglutide does not carry this warning. Women using oral birth control may need to add a barrier method or switch methods when starting or changing dose. Discuss this with your prescriber before starting, since it is a real clinical consideration, not just a cost one.
- Am I eligible for tirzepatide for weight loss?
- For Zepbound, the FDA label eligibility is a BMI of 30 or higher, or a BMI of 27 or higher together with at least one weight-related condition such as hypertension, type 2 diabetes, or dyslipidemia. A licensed prescriber confirms eligibility during a medical evaluation. Meeting these criteria also matters for insurance, since covered plans often require documentation of them.
Primary sources
ClearHormones publishes editorial health information for education only — not medical advice.